Lynparza 150 mg, 100 mg FC tablets
PDF Leaflet Revision Date: 29 February 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Maintenance treatment for specific cancers with BRCA mutations.
Dosage (summary)
300 mg (2 x 150 mg tablets) twice daily.
Special Populations
- Elderly (>65 years)
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated during pregnancy and breastfeeding; use effective contraception.
Key Drug Interactions
- Strong or moderate CYP3A inhibitors
- Strong or moderate CYP3A inducers
Contraindications
- Hypersensitivity
- Severe renal impairment (CrCl < 30 ml/min)
- Severe hepatic impairment (Child-Pugh class C)
- Pregnancy and lactation
Common side effects
- Anaemia
- Neutropenia
- Fatigue
- Nausea
- Vomiting
Counselling Points
- Monitor for haematological toxicity.
- Avoid pregnancy during treatment.
- Take with or without food.
Serious warnings
- Haematological toxicity
- Myelodysplastic Syndrome/Acute Myeloid Leukaemia
- Pneumonitis
Important Disclaimer
The Lynparza 150 mg, 100 mg FC tablets professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
